Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R-Mini-CYVE) regimen for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma not eligible for intensive chemotherapy.

Pamela AbdayemNathalie IbrahimYolla El DakdoukiChristophe WillekensDavid GhezJulia A RouchePeggy DartiguesRomain DesmarisAlina DanuJulien RossignolJulien LazaroviciChristophe FerméVincent RibragJean Marie Michot

Published in: European journal of haematology (2021)

R-mini-CYVE demonstrated a meaningful antitumour efficacy and an acceptable safety profile in patients with relapsed/refractory B-cell NHL who were ineligible for HDT.

Keyphrases

hodgkin lymphoma
diffuse large b cell lymphoma
acute myeloid leukemia
high dose
acute lymphoblastic leukemia
multiple myeloma
low dose
locally advanced
squamous cell carcinoma
rectal cancer